Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
321. |
ECCT/24/02/06 | INAVO122 A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in… read more |
Principal Investigator(s) 1. Dr Sitna Ali Site(s) in Kenya University of Nairobi -Institute of Tropical and Infectious Diseases |
View |
322. |
ECCT/24/06/03 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a… read more |
Principal Investigator(s) 1. Dr Walter Otieno Site(s) in Kenya 1. KEMRI-USAMRD-A Kombewa Clinical Research Centre (Kisumu county) |
View |
323. |
ECCT/23/12/01 | PEARL RSVt Vaccine Study Phase III, randomized, observer-blind, placebo-controlled, multi-center, multinational study to evaluate the efficacy, immunogenicity, and safety of a… read more |
Principal Investigator(s) 1. Prof Walter Jaoko 2. Dr. Lucas Thina Otieno 3. Prof. Kariuki Simon 4. Dr. Janet Nyawira Oyieko 5. Walter Otieno 6. Onono Dr. Marcianah 7. Dr. Lucas Thina Otieno 8. Prof.… read more |
View |
324. |
ECCT/23/07/03 |
ARNASA A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Professor Videlis Nduba 2. Professor Videlis Nduba Site(s) in Kenya 1. KENYA MEDICAL RESEARCH INSTITUTE-CENTRE FOR RESPIRATORY… read more |
View |
325. |
ECCT/23/08/01 |
ARNASA A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ASTEGOLIMAB IN PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE |
Principal Investigator(s) 1. Dr Teresa Kinyari Site(s) in Kenya 1. University of Nairobi Clinical Research Centre (Nairobi City county) 2. Center for… read more |
View |